Drug intelligence / Profile preview

MG1109

Development stage: Phase 3
Lead developer: 绿十字
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MG1109 is an egg-based, alum-adjuvanted, whole virion pre-pandemic influenza A/H5N1 vaccine developed as part of pandemic preparedness plans. In Phase III clinical trials, it demonstrated high immunogenicity with seroprotection rates of 74.8% after two doses. The vaccine met all three Committee for Medicinal Products for Human Use (CHMP) criteria against the vaccine strain across all age groups. Solicited adverse events were mostly mild to moderate and not significantly different from placebo.

Beyond the preview

Go deeper on MG1109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG1109.

Explore the full profile